OncoMatch/Clinical Trials/NCT07216105
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Is NCT07216105 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including FT836 and Paclitaxel for non-small cell lung cancer.
Treatment: FT836 · Paclitaxel · Cetuximab · Trastuzumab — This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
disease that has relapsed or progressed following at least one line of prior systemic therapy
Cannot have received: biological therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: chemotherapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: investigational therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Cannot have received: radiation therapy
Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter.
Lab requirements
Blood counts
ANC >1000/µL without growth factor support within 7 days; Platelet count ≥75,000/µL without transfusion support within 14 days
Kidney function
Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
Liver function
Total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert syndrome); AST ≤3 × ULN or ALT ≤3 × ULN (≤5 × ULN with liver metastases); ALP ≤2.5 × ULN (≤5 × ULN with liver or bone metastases)
Cardiac function
Oxygen saturation >90% on room air
Evidence of adequate organ function as determined by all of the following: ANC >1000/µL without growth factor support within 7 days prior to start of first study intervention; Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention; Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method; Total bilirubin ≤1.5 × ULN; for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN; AST ≤3 × ULN or ALT ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN; ALP ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN; Oxygen saturation >90% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Minnesota Masonic Cancer Center · Minneapolis, Minnesota
- Thomas Jefferson University, Sidney Kimmel Cancer Center · Philadelphia, Pennsylvania
- M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07216105 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior biological therapy, chemotherapy, investigational therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify